Company Description
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.
It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.
It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders.
The company was founded in 2018 and is based in Dublin, Ireland.
| Country | Ireland |
| Founded | 2018 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Velichka Valcheva |
Contact Details
Address: Joshua Dawson House, Dawson Street Dublin, D02 RY95 Ireland | |
| Phone | 353 1 437 8334 |
| Website | ghres.com |
Stock Details
| Ticker Symbol | GHRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001855129 |
| CUSIP Number | G3855L106 |
| ISIN Number | IE000GID8VI0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Velichka Valcheva M.D. | Chief Executive Officer |
| Florian Schonharting M.Sc. (Econ) | Co-Founder and Non-Executive Chairman of the Board |
| Magnus Halle | Co-Founder and MD of Ireland |
| Julie Ryan F.C.A. | Vice President of Finance |
| Aaron Cameron M.B.A. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 20, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 24, 2024 | 6-K | Report of foreign issuer |
| May 15, 2024 | 6-K | Report of foreign issuer |
| May 3, 2024 | 6-K | Report of foreign issuer |